Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation Announce New Launch of Mounjaro® 7.5 mg /10 mg /12.5 mg /15 mg Ateos®
Monday, June 12, 2023
Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation announced that “Mounjaro® subcutaneous injection 7.5 mg /10 mg /12.5 mg /15 mg ATEOS®” (Nonproprietary name: Tirzepatide, hereinafter referred called “Mounjaro”), the following sustained release GIP/GLP-1 receptor agonists, was launched in Japan.
Mounjaro® is a unique medication that combines the properties of both GIP (glucose-dependant insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists.
Mounjaro® is a medication that is administered once weekly by subcutaneous injection using a single-use autoinjector device called ATEOS. The autoinjector device is equipped with a pre-installed needle, and the injection process is automated.
Mounjaro® is a sustained-release GIP/GLP-1 receptor agonist, and it is available in different strengths: 7.5 mg, 10 mg, 12.5 mg, and 15 mg. This lineup of Mounjaro® provides options for different dosages to suit individual patient needs.
By selectively targeting and activating these receptors, Mounjaro® is designed to improve blood glucose levels. The sustained-release formulation of the medication ensures that its effects last for an extended period, providing a prolonged action to help regulate blood glucose over time.
To administer Mounjaro®, the patient places the autoinjector against their skin and presses the injection button. The needle is automatically inserted under the skin, and a single dose of the filled drug is injected. The patient does not need to set the dose or handle the needle manually, as the device takes care of these steps.
https://www.mt-pharma.co.jp/e/news/assets/pdf/e_MTPC230612.pdf
